BBP-671
Pantothenate Kinase-Associated Neurodegeneration (PKAN)
Key Facts
About CoA Therapeutics
CoA Therapeutics is a clinical-stage biotech developing small-molecule activators of pantothenate kinase (PanK) to restore CoA levels in severe metabolic and neurodegenerative disorders. Its lead program, BBP-671, is in Phase 1 development for PKAN and organic acidurias, with initial data showing promise in healthy volunteers. The company is a subsidiary of BridgeBio Pharma, leveraging its parent's operational and development expertise to advance treatments for diseases with high unmet need.
View full company profileAbout CoA Therapeutics
CoA Therapeutics is a clinical-stage biotech developing small-molecule activators of pantothenate kinase (PanK) to restore CoA levels in severe metabolic and neurodegenerative disorders. Its lead program, BBP-671, is in Phase 1 development for PKAN and organic acidurias, with initial data showing promise in healthy volunteers. The company is a subsidiary of BridgeBio Pharma, leveraging its parent's operational and development expertise to advance treatments for diseases with high unmet need.
View full company profile